Home › Colon Cancer › Arizona › Gilbert
Colon Cancer clinical trials in Gilbert, AZ
4 studies for Colon Cancer are looking for participants at sites in and around Gilbert (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Shield Post-Approval Study Protocol
RecruitingObservational studyHealthy volunteers welcome
- Southeast Valley Gastroenterology Consultants, Gilbert
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Banner Gateway Medical Center, Gilbert
- Banner MD Anderson Cancer Center, Gilbert
- Ironwood Cancer & Research Centers, Gilbert
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Banner Health, Gilbert
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Banner MD Anderson Cancer Center, Gilbert
Colon Cancer trials in other cities
- New York City, NY24 studies
- Boston, MA23 studies
- Houston, TX20 studies
- Nashville, TN17 studies
- Los Angeles, CA17 studies
- Chicago, IL16 studies
- Arlington, VA15 studies
- Seattle, WA15 studies
- Tampa, FL15 studies
- Baltimore, MD14 studies
- St. Louis, MO14 studies
- San Antonio, TX14 studies
Other studies in Gilbert
- Non-Small Cell Lung Cancer13 studies
- Breast Cancer9 studies
- Colorectal Cancer9 studies
- Cancer (all types)8 studies
- Lung Cancer8 studies
- Multiple Myeloma7 studies
- Bladder Cancer6 studies
- Heart Failure6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Metastatic Cancer6 studies
- Cardiovascular Disease5 studies
- Pancreatic Cancer5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.